Second Surgery for Many Ovarian Cancers Found Ineffective

November 14, 2019 5:00 pm

By Gene Emery

Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more

Genetically Definable Subgroups of Cancers Sensitive to Treatment

October 24, 2019 5:00 pm

Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more

FDA Approves Zejula for Advanced Ovarian Cancer Subset

October 23, 2019 3:30 pm

By Jessica Skarzynski

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

UCSD Researchers Find FAK Protein Linked to Chemotherapy Resistance in Ovarian Cancer

September 12, 2019 5:00 pm

Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. 

A new study in Read more

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?

August 26, 2019 7:00 pm

By Dave Levitan

The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more

AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study

August 13, 2019 5:15 am

By John Lauerman

AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.

Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more

Ovarian Cancer: Is this the Beginning of the End?

August 10, 2019 6:00 pm

By Michael J. Birrer, MD, PhD

There will be 22,530 new cases of ovarian cancer in the United States this year.

Although tumors often present at an advanced stage, it remains one of the most chemosensitive epithelial cancers, with a … Read more

Discovery of New “Don’t Eat Me Protein” Points the Way to Effective Cancer Therapy

August 1, 2019 4:00 pm

By Alexandru Micu

Stanford University (SU) researchers have found a new signaling molecule that cancer cells use to keep the immune system at bay.

Our bodies’ immune cells are, among other objectives, tasked with clearing out malfunctioning cells. In theory, … Read more

New Discovery Could Open Up PARP Inhibitors to More Cancer Patients

July 25, 2019 4:00 pm

By Amirah Al Idrus

PARP inhibitors have transformed treatment for breast and ovarian cancers, but their use has been limited to the small proportion of patients who have BRCA mutations. New research out of UT Southwestern Medical Center has uncovered … Read more

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer

July 23, 2019 5:00 pm

By Dave Levitan

A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.

“Up to … Read more

Targeting a Key Protein May Keep Ovarian Cancer Cells from Spreading

July 15, 2019 12:50 pm

By Zachary Sweger

Preventing a protein from doing its job may keep a certain type of ovarian cancer cell from growing and dividing uncontrollably in the lab, according to a new study from Penn State College of Medicine.

In … Read more

New Program Helps Patients with Advanced Cancer Access Experimental Drugs

July 11, 2019 7:00 pm

By Jack Elliot

In June 2019, the FDA announced a new program called “Project Facilitate” that is designed exclusively for patients with advanced cancer who have exhausted all available treatment options and are unable to participate in clinical trials. Through Read more

The Need for Clinical Trial Navigators

June 20, 2019 5:00 pm

Our Clinical Trial Finder is a personalized and online search tool that will help you to find a clinical trial based on your location or clinical situation (i.e. platinum sensitive or platinum resistant, number of previous treatments). We can also Read more

Novel Treatment Turns Tumors Into ‘Cancer Vaccine Factories’

June 13, 2019 5:00 pm

By Mark L. Fuerst

In-situ vaccine may enhance immunotherapy response in resistant cancers, study shows.

A novel approach to cancer immunotherapy injects immune stimulants directly into a tumor to “teach,” induce the immune system to destroy the cancer and other

Read more